Article

Three questions may help distinguish stress, urge incontinence

A three-question, noninvasive test appears to accurately classify stress and urge incontinence, according to a study in the Annals of Internal Medicine (2006; 144:715-23).

A three-question, noninvasive test appears to accurately classify stress and urge incontinence, according to a study in the Annals of Internal Medicine (2006; 144:715-23).

The multicenter study enrolled 301 women (mean age, 56 years) with untreated incontinence for an average of 7 years and a range of incontinence severity. The women answered three incontinence questions that comprise the 3IQ test and then responded to an extended evaluation to determine urge or stress incontinence.

The responses to the three questions were compared with responses of the extended evaluation, which was considered the gold standard. When classifying urge incontinence, the 3IQ questionnaire had a sensitivity of .75 (95% CI, .68-.81), specificity of .77 (CI, .69-.84), and a positive likelihood ratio of 3.29 (CI, 2.39 to 4.51). When classifying stress incontinence, the questionnaire had a sensitivity of .86 (CI, .79-.90), specificity of .60 (CI, .51-.68), and a positive likelihood ratio of 2.13 (CI 1.71-2.66).

Researchers, led by Jeannette S. Brown, MD, of the University of California, San Francisco, acknowledged that similar studies are needed in other populations, and clinical trials are needed to compare the outcomes of treatments based on the three-question test and the extended evaluation.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Considering patient-reported outcomes in kidney cancer care, with Nicholas Zaorsky, MD, PhD
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
 Nicholas Zaorsky, MD, MS: Protecting kidney function after local renal cell carcinoma therapy
Daniel Carson, MD, MS, answers a question during a Zoom video interview
© 2024 MJH Life Sciences

All rights reserved.